Condition 1: Hyperthyroidism. Condition 2: anti-thyroid drugs. Thyrotoxicosis [hyperthyroidism]
Conditions
Interventions
Intervention 1: 100 µCi iodide 131 per gram of the thyroid In "radioiodine group". Intervention 2: Methimazole group: 10 mg of Methimazole twice daily during the first month and 10 mg daily during the
Sponsors
Research Institute for Endocrine Sciences,Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
19 Years to No maximum
Inclusion criteria
Inclusion criteria: Age older than 19 years Biochemically defined overt hyperthyroidism No history or evidence of cardiovascular diseases No history or evidence of chronic heart failure No history or evidence of chronic kidney disease No history or evidence of cirrhosis
Exclusion criteria
Exclusion criteria: Evidence of pregnancy Evidence of breast-feeding Evidence of altered mental function
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Serum lipid profiles. Timepoint: at the beginning and end of study (during study if needed). Method of measurement: laboratory.;Bone mineral density. Timepoint: at the end of study. Method of measurement: BMD.;Cost. Timepoint: During follow up and at the end of study. Method of measurement: from actual ambulatory and hospital expenses during follow up. | — |
Primary
| Measure | Time frame |
|---|---|
| Neuro-psychologic condition. Timepoint: at the beginning and end of study. Method of measurement: neuro-psychologic tests.;Development of Goiter. Timepoint: any visit and at the end of study. Method of measurement: physical exam.;Thyroid function assessment. Timepoint: Every 6 months during follow up and at the end of study. Method of measurement: laboratory.;Cardiac function. Timepoint: at the end of study. Method of measurement: echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFereidoun Azizi, M.D.
Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Siences
Outcome results
None listed